---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014708"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:34:52.485298+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M

## Summary
- Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.
- Updated XTX101 data: durable partial response 36 wks in NSCLC; no Grade 4/5 AEs at RP2D; no colitis.
- XTX202 cleared 2.8 mg/kg dose, no vascular leak; expects preliminary Phase 1/2 data early Nov 2023 in ≥20 evaluable pts.
- Q2 net loss $19.4M vs $24.6M YoY; cash $75.4M, runway into Q2 2024.
- Promoted Chris Frankenfield to COO; XTX301 safety data expected Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-014708
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/xlo-20230814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014708
- JSON: https://secwatch.observer/filing/0001558370-23-014708.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014708.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.